

# Clinical trials of antiplatelets drug for acute myocardial infarction in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 P2Y12 receptor antagonist

Trial	Treatments	Patients	Trials design and methods
<b>elinogrel vs error</b>			
<b>INNOVATE</b> <i>ongoing</i> [NCT00751231] n=NA follow-up:	-	-	
<b>elinogrel vs placebo</b>			
<b>ERASE-MI , 2009</b> n=34/36 follow-up: 30-37 days	elinogrel 10, 20, 40, or 60 mg as a single intravenous bolus versus placebo	STEMI patients	Parallel groups double blind

## References

**INNOVATE, :**  
**ERASE-MI, 2009:**

Berger JS, Roe MT, Gibson CM, Kilaru R, Green CL, Melton L, Blankenship JD, Metzger DC, Granger CB, Gretler DD, Grines CL, Huber K, Zeymer U, Buszman P, Harrington RA, Armstrong PW Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial. Am Heart J 2009;158:998-1004.e1 [[19958867](#)]

## 2 platelet aggregation inhibitors

Trial	Treatments	Patients	Trials design and methods
<b>aspirin vs control</b>			
<b>Huddinge , 1988</b> n=10/10 follow-up: 30d (12m)	aspirin 500mg/d starting 12 h after admission and then intermittently every third day for one month versus no aspirin	patients with acute myocardial infarction	Parallel groups open
<b>Frankfurt , 1976</b> n=25/28 follow-up: 14d	-	-	Parallel groups

continued...

Trial	Treatments	Patients	Trials design and methods
<b>dazoxiben vs control</b>			
Jones , 1987 n=60/60 follow-up: 1m	-	-	Parallel groups
<b>GR3219B vs control</b>			
GRAND , 1987 n=63/64 follow-up: 1m	-	-	Parallel groups
<b>misc. vs control</b>			
Gent-AMI , 1968 n=60/60 follow-up: 28d	-	-	Parallel groups
Johannessen , 1989 n=11/9 follow-up: 14d	-	-	Parallel groups
<b>sulfinpyrazone vs control</b>			
Dutch sulphinpyrazone , 1986 n=50/50 follow-up: 21d	-	-	Parallel groups
<b>ticlopidine vs control</b>			
Knudsen-A , 1985 n=24/19 follow-up: 3m	ticlopidine 500mg/d versus placebo	patients with AMI	Parallel groups double blind
<b>aspirin vs placebo</b>			
ISIS-pilot , 1987 n=313/306 follow-up: 1m	aspirin (325 mg on alternate days for 28 days) versus placebo	suspected acute myocardial infarction	Parallel groups double blind
ISIS-2 , 1988 n=8587/8600 follow-up: 35d	160 mg/day enteric-coated aspirin for one month versus placebo	suspected acute myocardial up to 24h	Parallel groups double blind
Dutch-aspirin , 1990 n=50/50 follow-up: 3m	aspirin (100 mg/day) for 3 months versus placebo	patients with first anterior wall AMI	Parallel groups double blind
APRICOT , 1993 n=107/95 follow-up: 3m	325 mg aspirin daily with discontinuation of heparin versus placebo	Patients treated with intravenous thrombolytic therapy followed by intravenous heparin and with patent infarct-related artery demonstrated at angiography within 48 hours	Parallel groups double blind The Netherlands
<b>clopidogrel vs placebo</b>			
CLARITY-TIMI 28 , 2005 n=NA follow-up: 30 days	clopidogrel (300-mg loading dose, followed by 75 mg once daily) versus placebo	patients, 18 to 75 years of age, within 12 hours after the onset of an ST-elevation myocardial infarction	double blind

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>COMMIT , 2005</b> [NCT00222573] n=22961/22891 follow-up: until discharge or up to 4 wee	clopidogrel 75 mg daily versus placebo	patients admitted to hospital within 24 h of suspected acute MI onset	Parallel groups double-blind
<b>flurbiprofen vs placebo</b>			
<b>French , 1993</b> n=234/230 follow-up: 6m	flurbiprofen 50 mg twice daily versus placebo	patients successfully treated for acute MI by thrombolysis and/or coronary angioplasty within 6 h of onset of symptoms	Parallel groups double blind
<b>sulfinpyrazone vs placebo</b>			
<b>Wilcox , 1980</b> n=49/49 follow-up: 10d	Sulphinpyrazone 200 mg four times daily versus placebo	patients with acute myocardial infarction	Parallel groups
<b>Louvain sulphinpyrazone , 1983</b> n=15/14 follow-up: 7d	sulphinpyrazone, 4 x 200 mg daily for 7 days versus placebo	recent myocardial infarction	Parallel groups double blind

## References

### Huddinge, 1988:

Rasmanis G, Vesterqvist O, Gren K, Edhag O, Henriksson P Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. *Lancet* 1988;2:245-7 [2899236]

### Frankfurt, 1976:

Asasantin DVT nach Myokardinfarktp, imag Boehringer Ingelheim, 1976. (Boehringer Ingelheim internal report.)

### Jones, 1987:

Jones EW. A study of dazoxiben in the prevention of venous thrombosis after suspected myocardial infarction (MD Thesis).<Nottingham: Nottingham University, 1987:111-24

### GRAND, 1987:

Mitchell JRA, for GRAND (Glaxo Receptor Antagonist against Nottingham DVT) Study Groupio Trial of thromboxane receptor antagonist as prophylaxis against deep vein thrombosis in suspected acute myocardial infarction Uxbridge, Middlesex: Glaxo, 1987. (Glaxo internal report.)m

### Gent-AMI, 1968:

Gent AE, Brook CG, Foley TH, Miller TN Dipyridamole: a controlled trial of its effect in acute myocardial infarction. *Br Med J* 1968;4:366-8 [4879059]

### Johannessen, 1989:

Johannessen KA, Stratton JR, Taulow E, Osterud B, von der Lippe G Usefulness of aspirin plus dipyridamole in reducing left ventricular thrombus formation in anterior wall acute myocardial infarction. *Am J Cardiol* 1989;63:101-2 [2642365]

### Dutch sulphinpyrazone, 1986:

Funke Kpper AJ, Verheugt FWA, Jaarsma W, Roos JP.age/pj Funke Kpper AJ, Verheugt FWA, Jaarsma W, Roos JP. Failure of sulphinpyrazone to prevent left ventricular thrombosis in patients with AMI treated with oral anticoagulants Proceedings of X World Congress of Cardiology. Washington: 1986:419 (Abstract 2414)atio

### Knudsen-A, 1985:

Knudsen JB, Kjller E, Skagen K, Gormsen J The effect of ticlopidine on platelet functions in acute myocardial infarction. A double blind controlled trial. *Thromb Haemost* 1985;53:332-6 [3901391]

### ISIS-pilot, 1987:

Randomized factorial trial of high-dose intravenous streptokinase, of oral aspirin and of intravenous heparin in acute myocardial infarction. ISIS (International Studies of Infarct Survival) pilot study. *Eur Heart J* 1987;8:634-42 [[2887430](#)]

**ISIS-2, 1988:**

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. *Lancet* 1988;2:349-60 [[2899772](#)]

**Dutch-aspirin, 1990:**

Verheugt FW, van der Laarse A, Funke-Kpper AJ, Sterkman LG, Galema TW, Roos JP Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. *Am J Cardiol* 1990;66:267-70 [[2195861](#)]

**APRICOT, 1993:**

Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige MJ Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study. Results of the APRICOT Study. *Circulation* 1993;87:1524-30 [[8491007](#)]

**CLARITY-TIMI 28, 2005:**

Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. *N Engl J Med* 2005 Mar 24;352:1179-89 [[15758000](#)]

**COMMIT, 2005:**

Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. *Lancet* 2005 Nov 5;366:1607-21 [[16271642](#)]

**French, 1993:**

Brochier ML Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction. The Flurbiprofen French Trial. *Eur Heart J* 1993;14:951-7 [[8375421](#)]

**Wilcox, 1980:**

Wilcox RG, Richardson D, Hampton JR, Mitchell JR, Banks DC Sulphinpyrazone in acute myocardial infarction: studies on cardiac rhythm and renal function. *Br Med J* 1980;281:531-4 [[7000264](#)]

**Louvain sulphinpyrazone, 1983:**

Lijnen P, Boelaert J, van Eeghem P, Daneels R, Schurgers M, de Jaegere P, van der Stichele E, Vincke J, Fagard R, Verschueren LJ, Amery A Decrease in renal function due to sulphinpyrazone treatment early after myocardial infarction. *Clin Nephrol* 1983;19:143-6 [[6340878](#)]

### 3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.